Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex
Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated li...
Saved in:
Published in | Drug metabolism and disposition Vol. 42; no. 1; pp. 78 - 88 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Inc
01.01.2014
The American Society for Pharmacology and Experimental Therapeutics |
Subjects | |
Online Access | Get full text |
ISSN | 0090-9556 1521-009X 1521-009X |
DOI | 10.1124/dmd.113.053819 |
Cover
Loading…
Abstract | Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling. |
---|---|
AbstractList | Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling. Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers ( n = 64) and cryopreserved human hepatocytes ( n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/ µ g of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher ( P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling. Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling.Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling. |
Author | Prasad, Bhagwat Unadkat, Jashvant D Ambudkar, Suresh V Hop, Cornelis E. C. A Gupta, Anshul Shukla, Suneet Evers, Raymond Salphati, Laurent |
Author_xml | – sequence: 1 givenname: Bhagwat surname: Prasad fullname: Prasad, Bhagwat – sequence: 2 givenname: Raymond surname: Evers fullname: Evers, Raymond – sequence: 3 givenname: Anshul surname: Gupta fullname: Gupta, Anshul – sequence: 4 givenname: Cornelis E. C. A surname: Hop fullname: Hop, Cornelis E. C. A – sequence: 5 givenname: Laurent surname: Salphati fullname: Salphati, Laurent – sequence: 6 givenname: Suneet surname: Shukla fullname: Shukla, Suneet – sequence: 7 givenname: Suresh V surname: Ambudkar fullname: Ambudkar, Suresh V – sequence: 8 givenname: Jashvant D surname: Unadkat fullname: Unadkat, Jashvant D email: jash@u.washington.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24122874$$D View this record in MEDLINE/PubMed |
BookMark | eNp1Uk1vEzEQXaEimhauHJGPRWLDer-y5lApjUoaKahBDYib5fXOJoN27a3tjbp_mN-B06QIkHrxG2vmvTeambPgRGkFQfCWRmNK4_Rj1VY-SMZRlhSUvQhGNItpGEXsx0kw8hCFLMvy0-DM2p9RRNM0Ya-C0zilcVxM0lHwa6EcGFQV7rDqRUO-C4OixAbdQFCRG-iEQ0luzUYoj1OFWoVrI5TttHGoNmSlm6GDzmEFlghVkVU4bwapO6MdeImL6dXsir4nq-P_-qEzYK3X-US-9kI5rFF6E61IOZAl3vdYkdnW6FY4vTGi2w5k7XWhJV-EteSuA-mMtt5hePRbqLrpQUkguiZzUNr5fj6Q6cY_-_wdPLwOXtaisfDmiOfBt8_X69lNuLydL2bTZSizKHMhyLRkVZ6UccFAClZVEvIkZ2lWpBnLClonULBCiDjLs6JmSTmp8yJnkKc0yWSSnAeXB92uL1vwbOWMaHhnsBVm4Fog_zejcMs3eseTYpJPWOQFLo4CRt_3YB1v0UpoGqFA95bTNGcx3ffjS9_97fXH5Gm5viA9FEg_LWug5hLd46C9NTacRnx_Q9zfkA8SfrghTxv_R3tSfpZQHAjgJ7tDMNxK3O-jQuNXxSuNz1F_AzQP4WQ |
CitedBy_id | crossref_primary_10_1016_j_jpba_2018_11_013 crossref_primary_10_1124_dmd_114_058446 crossref_primary_10_1146_annurev_anchem_091719_024553 crossref_primary_10_3389_fphys_2017_00123 crossref_primary_10_1124_dmd_114_061614 crossref_primary_10_1158_1078_0432_CCR_16_2245 crossref_primary_10_1111_cts_13444 crossref_primary_10_1002_psp4_12168 crossref_primary_10_1124_dmd_115_063362 crossref_primary_10_1002_hep4_1489 crossref_primary_10_1124_dmd_114_061580 crossref_primary_10_1124_dmd_120_000122 crossref_primary_10_3389_fphar_2015_00013 crossref_primary_10_1002_psp4_12170 crossref_primary_10_1124_dmd_115_064170 crossref_primary_10_1002_cpt_819 crossref_primary_10_1124_jpet_119_263459 crossref_primary_10_1039_D3MO00144J crossref_primary_10_1124_dmd_118_084988 crossref_primary_10_1038_s41598_019_45778_9 crossref_primary_10_1021_acs_molpharmaceut_8b01189 crossref_primary_10_1002_prp2_1082 crossref_primary_10_1124_dmd_114_062034 crossref_primary_10_1016_j_ejps_2018_08_042 crossref_primary_10_1007_s11095_019_2634_3 crossref_primary_10_3390_ijms17091502 crossref_primary_10_1124_dmd_117_076703 crossref_primary_10_1124_pharmrev_121_000449 crossref_primary_10_1016_j_ab_2016_06_006 crossref_primary_10_1096_fasebj_31_1_supplement_669_13 crossref_primary_10_1208_s12248_014_9602_y crossref_primary_10_3390_pharmaceutics14050915 crossref_primary_10_1002_jcph_671 crossref_primary_10_1128_AAC_00955_20 crossref_primary_10_1016_j_ddtec_2021_06_002 crossref_primary_10_1124_dmd_121_000805 crossref_primary_10_1016_j_ddtec_2021_06_008 crossref_primary_10_1124_dmd_113_056309 crossref_primary_10_1016_j_bcp_2021_114534 crossref_primary_10_1021_acs_molpharmaceut_8b00941 crossref_primary_10_1038_s41420_021_00621_x crossref_primary_10_1124_dmd_114_056929 crossref_primary_10_1039_D4AN01514B crossref_primary_10_1007_s11095_014_1446_8 crossref_primary_10_1002_prca_201400147 crossref_primary_10_1124_dmd_114_057976 crossref_primary_10_1016_j_xphs_2017_03_027 crossref_primary_10_3390_pharmaceutics9010008 crossref_primary_10_1002_cpt_409 crossref_primary_10_1002_jcph_703 crossref_primary_10_29413_ABS_2021_6_6_2_12 crossref_primary_10_1124_dmd_114_059873 crossref_primary_10_1016_j_jchromb_2019_01_005 crossref_primary_10_1007_s11095_016_1966_5 crossref_primary_10_1208_s12248_019_0359_1 crossref_primary_10_1007_s40268_019_00285_0 crossref_primary_10_1016_j_xphs_2017_03_023 crossref_primary_10_3389_fnbeh_2022_844916 crossref_primary_10_1002_cpt_1373 crossref_primary_10_1124_dmd_119_089656 crossref_primary_10_1016_j_pharmr_2024_100023 crossref_primary_10_1124_dmd_119_086785 crossref_primary_10_1002_jcph_1489 crossref_primary_10_1093_toxsci_kfw236 crossref_primary_10_3109_03602532_2014_882353 crossref_primary_10_1016_j_ejps_2020_105395 crossref_primary_10_1002_cpt_1537 crossref_primary_10_1016_j_pharmthera_2019_107397 crossref_primary_10_1007_s11095_022_03387_8 crossref_primary_10_1016_j_jpba_2015_02_043 crossref_primary_10_3390_biomedicines11061633 crossref_primary_10_1124_dmd_121_000476 crossref_primary_10_1124_dmd_116_072066 crossref_primary_10_1080_17460441_2018_1493454 crossref_primary_10_3389_fphar_2021_715577 crossref_primary_10_1038_s41598_019_46977_0 crossref_primary_10_1124_dmd_115_067538 crossref_primary_10_1016_j_apsb_2025_03_030 crossref_primary_10_1096_fasebj_31_1_supplement_668_17 crossref_primary_10_1124_dmd_115_067371 crossref_primary_10_1124_dmd_118_080952 crossref_primary_10_1016_j_bcp_2014_09_025 crossref_primary_10_1016_j_ejps_2020_105264 crossref_primary_10_1124_dmd_116_071183 crossref_primary_10_1002_cpt_2556 crossref_primary_10_1080_17425255_2018_1546288 crossref_primary_10_3390_molecules25112718 crossref_primary_10_1016_j_ijpharm_2016_04_024 crossref_primary_10_1124_dmd_116_074732 crossref_primary_10_1124_dmd_117_077289 crossref_primary_10_1124_dmd_116_074575 crossref_primary_10_1038_psp_2014_24 crossref_primary_10_3109_03602532_2014_921190 crossref_primary_10_1124_dmd_115_067801 crossref_primary_10_1124_dmd_115_068577 crossref_primary_10_3109_00498254_2015_1085111 crossref_primary_10_1155_2014_451510 crossref_primary_10_1002_jps_24336 crossref_primary_10_1016_j_ejps_2022_106246 crossref_primary_10_1124_dmd_117_076745 crossref_primary_10_1124_jpet_117_243113 crossref_primary_10_1007_s11883_017_0701_y crossref_primary_10_1021_acs_molpharmaceut_1c00083 crossref_primary_10_1097_HC9_0000000000000031 crossref_primary_10_1002_cpt_176 crossref_primary_10_1124_dmd_121_000451 crossref_primary_10_1080_03602532_2021_1922435 crossref_primary_10_1124_dmd_117_076463 crossref_primary_10_1208_s12248_014_9607_6 crossref_primary_10_1080_10408347_2021_1891859 crossref_primary_10_2217_pgs_15_18 crossref_primary_10_1124_dmd_115_069252 crossref_primary_10_18632_oncotarget_13135 crossref_primary_10_1093_toxsci_kfv110 crossref_primary_10_1517_17425255_2015_1055245 crossref_primary_10_1016_j_dmpk_2015_06_005 crossref_primary_10_1007_s11095_021_03107_8 crossref_primary_10_1124_dmd_116_072652 crossref_primary_10_3109_03602532_2016_1157600 crossref_primary_10_1208_s12248_016_0009_9 crossref_primary_10_1124_pharmrev_120_000071 crossref_primary_10_1002_jcph_740 crossref_primary_10_1080_17425255_2025_2481891 crossref_primary_10_1080_17425255_2020_1749595 crossref_primary_10_3389_fphys_2021_757293 crossref_primary_10_1124_dmd_118_080523 crossref_primary_10_1016_j_apsb_2022_03_009 crossref_primary_10_1002_cpt_3354 crossref_primary_10_1038_tpj_2015_58 crossref_primary_10_1016_j_phrs_2017_01_018 crossref_primary_10_1016_j_ejps_2019_01_022 crossref_primary_10_1159_000362822 crossref_primary_10_1007_s40262_014_0156_z crossref_primary_10_1111_bcp_14230 crossref_primary_10_1124_dmd_116_071050 crossref_primary_10_1038_s41401_021_00692_7 crossref_primary_10_3390_pharmaceutics14081734 crossref_primary_10_1016_j_pharep_2019_04_001 crossref_primary_10_1016_j_jchromb_2017_07_051 crossref_primary_10_1007_s40262_015_0267_1 crossref_primary_10_1007_s40262_015_0328_5 crossref_primary_10_1002_cyto_b_21729 crossref_primary_10_1002_jcph_695 crossref_primary_10_1124_dmd_120_000134 crossref_primary_10_1016_j_jchromb_2018_03_007 crossref_primary_10_1002_mnfr_201400095 crossref_primary_10_1002_jcph_1604 crossref_primary_10_1007_s13318_022_00802_8 crossref_primary_10_1016_j_xphs_2016_11_017 crossref_primary_10_1096_fasebj_30_1_supplement_713_11 crossref_primary_10_1021_acs_molpharmaceut_8b00320 |
Cites_doi | 10.1002/rcm.5026 10.1038/clpt.2010.255 10.1111/j.1365-2125.2008.03287.x 10.1097/FPC.0b013e32830d733e 10.1515/cclm.2011.804 10.3851/IMP2095 10.1021/jm300212s 10.1002/hep.21214 10.1124/dmd.111.043489 10.1074/jbc.M103792200 10.1016/j.bcp.2011.10.017 10.1016/j.aca.2011.12.005 10.1615/CritRevBiomedEng.v40.i4.50 10.1161/CIRCGENETICS.109.898502 10.1097/01.fpc.0000170913.73780.5f 10.1097/01.fpc.0000114750.08559.32 10.1038/clpt.2009.232 10.1007/s11095-012-0956-5 10.1074/jbc.M601917200 10.1016/j.clpt.2003.12.014 10.1124/jpet.104.068536 10.1067/mcp.2002.128469 10.1002/jps.23436 10.3390/ijms12095815 10.1016/S0014-2565(01)70966-6 10.1124/dmd.111.043810 10.1517/17425255.2013.741589 10.1016/S0002-9343(00)00514-3 10.1097/FPC.0b013e328335b02d 10.1016/j.clpt.2003.12.016 10.1007/s11095-008-9532-4 10.1056/NEJMoa0801936 10.1186/gm405 10.1002/bdd.1810 10.1016/j.ejps.2005.12.003 10.1016/j.jacc.2009.04.053 10.1007/s11095-012-0792-7 10.1124/dmd.111.042275 10.1021/mp300379q 10.1038/nrd3028 10.1124/dmd.111.042259 10.1016/S0022-3565(24)37149-6 |
ContentType | Journal Article |
Copyright | 2013 American Society for Pharmacology and Experimental Therapeutics U.S. Government work not protected by U.S. copyright 2014 |
Copyright_xml | – notice: 2013 American Society for Pharmacology and Experimental Therapeutics – notice: U.S. Government work not protected by U.S. copyright 2014 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1124/dmd.113.053819 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Interindividual Variability in Hepatic Transporter Expression |
EISSN | 1521-009X |
EndPage | 88 |
ExternalDocumentID | PMC3876790 24122874 10_1124_dmd_113_053819 S0090955624098118 |
Genre | Research Support, U.S. Gov't, P.H.S Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Intramural NIH HHS grantid: ZIA BC010030 – fundername: NCI NIH HHS grantid: ZIA BC010030-13 |
GroupedDBID | --- .GJ 0R~ 18M 2WC 4.4 53G 5GY 5RE 5VS AAXUO ABJNI ABSQV ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AERNN AFFNX AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC KQ8 LSO M41 O9- OK1 P2P R0Z RHI ROL RPT SJN TR2 VH1 W8F WH7 WOQ YCJ YHG ZGI ZXP ~KM AALRI AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c505t-ec4b9d63b289eca9ddce6369458459581f3e898aa25658f93b7f6869e64135c33 |
ISSN | 0090-9556 1521-009X |
IngestDate | Thu Aug 21 14:33:09 EDT 2025 Fri Jul 11 14:16:40 EDT 2025 Mon Jul 21 05:54:39 EDT 2025 Thu Apr 24 23:08:39 EDT 2025 Tue Jul 01 05:28:21 EDT 2025 Sun Apr 06 06:53:01 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | BCRP BCA P-gp DDI PBPK CL MRM OATP AUC LC-MS/MS MRP-2 SNP SIL |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c505t-ec4b9d63b289eca9ddce6369458459581f3e898aa25658f93b7f6869e64135c33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 R.E., A.G., C.E.H., and L.S. contributed equally to the research. |
OpenAccessLink | https://dmd.aspetjournals.org/content/dmd/42/1/78.full.pdf |
PMID | 24122874 |
PQID | 1469214584 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3876790 proquest_miscellaneous_1469214584 pubmed_primary_24122874 crossref_citationtrail_10_1124_dmd_113_053819 crossref_primary_10_1124_dmd_113_053819 elsevier_sciencedirect_doi_10_1124_dmd_113_053819 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | January 2014 2014-01-00 2014-Jan 20140101 |
PublicationDateYYYYMMDD | 2014-01-01 |
PublicationDate_xml | – month: 01 year: 2014 text: January 2014 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Bethesda, MD |
PublicationTitle | Drug metabolism and disposition |
PublicationTitleAlternate | Drug Metab Dispos |
PublicationYear | 2014 |
Publisher | Elsevier Inc The American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: Elsevier Inc – name: The American Society for Pharmacology and Experimental Therapeutics |
References | Marsà Carretero, Alos Manrique, Valles Callol (bib24) 2002; 52 Alexandridis, Pappas, Elisaf (bib2) 2000; 109 Link, Parish, Armitage, Bowman, Heath, Matsuda, Gut, Lathrop, Collins (bib22) 2008; 359 Rodrigues, Perin, Purim, Silbiger, Genvigir, Willrich, Arazi, Luchessi, Hirata, Bernik (bib34) 2011; 12 Varma, Lai, Feng, Litchfield, Goosen, Bergman (bib45) 2012; 29 Kameyama, Yamashita, Kobayashi, Hosokawa, Chiba (bib18) 2005; 15 Ohtsuki, Schaefer, Kawakami, Inoue, Liehner, Saito, Ishiguro, Kishimoto, Ludwig-Schwellinger, Ebner (bib30) 2012; 40 Zhang, Li, Brown, Ozer, Lai (bib48) 2011; 25 Sortica, Fiegenbaum, Lima, Van der Sand, Van der Sand, Ferreira, Pires, Hutz (bib41) 2012; 50 Shitara, Hirano, Sato, Sugiyama (bib39) 2004; 311 Karlgren, Vildhede, Norinder, Wisniewski, Kimoto, Lai, Haglund, Artursson (bib20) 2012; 55 Giacomini, Huang, Tweedie, Benet, Brouwer, Chu, Dahlin, Evers, Fischer, Hillgren (bib11) 2010; 9 Bailey, Romaine, Jackson, Farrin, Efthymiou, Barth, Copeland, McCormack, Whitehead, Flather (bib4) 2010; 3 Kalliokoski, Neuvonen, Neuvonen, Niemi (bib17) 2008; 66 Meier, Pauli-Magnus, Zanger, Klein, Schaeffeler, Nussler, Nussler, Eichelbaum, Meier, Stieger (bib26) 2006; 44 Mwinyi, Johne, Bauer, Roots, Gerloff (bib27) 2004; 75 Harwood, Neuhoff, Carlson, Warhurst, Rostami-Hodjegan (bib13) 2013; 34 Sauna, Nandigama, Ambudkar (bib35) 2006; 281 Prasad, Lai, Lin, Unadkat (bib33) 2013; 102 Tomlinson, Hu, Lee, Lui, Chu, Poon, Ko, Baum, Tam, Li (bib43) 2010; 87 Varma, Lai, Kimoto, Goosen, El-Kattan, Kumar (bib46) 2013; 30 Kimoto, Yoshida, Balogh, Bi, Maeda, El-Kattan, Sugiyama, Lai (bib21) 2012; 9 Schneck, Birmingham, Zalikowski, Mitchell, Wang, Martin, Lasseter, Brown, Windass, Raza (bib38) 2004; 75 Deo, Prasad, Balogh, Lai, Unadkat (bib9) 2012; 40 Hartkoorn, Kwan, Shallcross, Chaikan, Liptrott, Egan, Sora, James, Gibbons, Bray (bib12) 2010; 20 Tucker, Milne, Fournel-Gigleux, Fenner, Coughtrie (bib44) 2012; 83 Donnelly, Doney, Tavendale, Lang, Pearson, Colhoun, McCarthy, Hattersley, Morris, Palmer (bib10) 2011; 89 Schipani, Egan, Dickinson, Davies, Boffito, Youle, Khoo, Back, Owen (bib37) 2012; 17 Backman, Kyrklund, Neuvonen, Neuvonen (bib3) 2002; 72 Bi, Kimoto, Sevidal, Jones, Barton, Kempshall, Whalen, Zhang, Ji, Fenner (bib6) 2012; 40 Lon, Liu, Jusko (bib23) 2012; 40 Kamiie, Ohtsuki, Iwase, Ohmine, Katsukura, Yanai, Sekine, Uchida, Ito, Terasaki (bib19) 2008; 25 Balogh, Kimoto, Chupka, Zhang, Lai (bib5) 2012; 84 Tirona, Leake, Merino, Kim (bib42) 2001; 276 Bosch Rovira, Llompart Pou, Forteza-Rey (bib7) 2001; 201 Voora, Shah, Spasojevic, Ali, Reed, Salisbury, Ginsburg (bib47) 2009; 54 Niemi, Schaeffeler, Lang, Fromm, Neuvonen, Kyrklund, Backman, Kerb, Schwab, Neuvonen (bib28) 2004; 14 Chu, Bleasby, Evers (bib8) 2013; 9 Kalliokoski, Backman, Neuvonen, Niemi (bib16) 2008; 18 Ji, Tschantz, Pfeifer, Ullah, Sadagopan (bib14) 2012; 717 Shitara, Horie, Sugiyama (bib40) 2006; 27 Paine, Khalighi, Fisher, Shen, Kunze, Marsh, Perkins, Thummel (bib31) 1997; 283 Schaefer, Ohtsuki, Kawakami, Inoue, Liehner, Saito, Sakamoto, Ishiguro, Matsumaru, Terasaki (bib36) 2012; 40 Nies, Niemi, Burk, Winter, Zanger, Stieger, Schwab, Schaeffeler (bib29) 2013; 5 Marsà Carretero (10.1124/dmd.113.053819_bib24) 2002; 52 Shitara (10.1124/dmd.113.053819_bib39) 2004; 311 Varma (10.1124/dmd.113.053819_bib46) 2013; 30 Hartkoorn (10.1124/dmd.113.053819_bib12) 2010; 20 Sauna (10.1124/dmd.113.053819_bib35) 2006; 281 Deo (10.1124/dmd.113.053819_bib9) 2012; 40 Prasad (10.1124/dmd.113.053819_bib33) 2013; 102 Meier (10.1124/dmd.113.053819_bib26) 2006; 44 Chu (10.1124/dmd.113.053819_bib8) 2013; 9 Shitara (10.1124/dmd.113.053819_bib40) 2006; 27 Kameyama (10.1124/dmd.113.053819_bib18) 2005; 15 Kalliokoski (10.1124/dmd.113.053819_bib16) 2008; 18 Niemi (10.1124/dmd.113.053819_bib28) 2004; 14 Harwood (10.1124/dmd.113.053819_bib13) 2013; 34 Schipani (10.1124/dmd.113.053819_bib37) 2012; 17 Bailey (10.1124/dmd.113.053819_bib4) 2010; 3 Donnelly (10.1124/dmd.113.053819_bib10) 2011; 89 Lon (10.1124/dmd.113.053819_bib23) 2012; 40 Mwinyi (10.1124/dmd.113.053819_bib27) 2004; 75 Sortica (10.1124/dmd.113.053819_bib41) 2012; 50 Bosch Rovira (10.1124/dmd.113.053819_bib7) 2001; 201 Nies (10.1124/dmd.113.053819_bib29) 2013; 5 Backman (10.1124/dmd.113.053819_bib3) 2002; 72 Ohtsuki (10.1124/dmd.113.053819_bib30) 2012; 40 Rodrigues (10.1124/dmd.113.053819_bib34) 2011; 12 Zhang (10.1124/dmd.113.053819_bib48) 2011; 25 Varma (10.1124/dmd.113.053819_bib45) 2012; 29 Alexandridis (10.1124/dmd.113.053819_bib2) 2000; 109 Schaefer (10.1124/dmd.113.053819_bib36) 2012; 40 Kalliokoski (10.1124/dmd.113.053819_bib17) 2008; 66 Giacomini (10.1124/dmd.113.053819_bib11) 2010; 9 Paine (10.1124/dmd.113.053819_bib31) 1997; 283 Link (10.1124/dmd.113.053819_bib22) 2008; 359 Schneck (10.1124/dmd.113.053819_bib38) 2004; 75 Voora (10.1124/dmd.113.053819_bib47) 2009; 54 Tucker (10.1124/dmd.113.053819_bib44) 2012; 83 Kimoto (10.1124/dmd.113.053819_bib21) 2012; 9 Balogh (10.1124/dmd.113.053819_bib5) 2012; 84 Kamiie (10.1124/dmd.113.053819_bib19) 2008; 25 Ji (10.1124/dmd.113.053819_bib14) 2012; 717 Bi (10.1124/dmd.113.053819_bib6) 2012; 40 Karlgren (10.1124/dmd.113.053819_bib20) 2012; 55 Tirona (10.1124/dmd.113.053819_bib42) 2001; 276 Tomlinson (10.1124/dmd.113.053819_bib43) 2010; 87 |
References_xml | – volume: 72 start-page: 685 year: 2002 end-page: 691 ident: bib3 article-title: Gemfibrozil greatly increases plasma concentrations of cerivastatin publication-title: Clin Pharmacol Ther – volume: 18 start-page: 937 year: 2008 end-page: 942 ident: bib16 article-title: Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide publication-title: Pharmacogenet Genomics – volume: 201 start-page: 731 year: 2001 end-page: 732 ident: bib7 article-title: [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil] publication-title: Rev Clin Esp – volume: 25 start-page: 1715 year: 2011 end-page: 1724 ident: bib48 article-title: Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples publication-title: Rapid Commun Mass Spectrom – volume: 40 start-page: 93 year: 2012 end-page: 103 ident: bib36 article-title: Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes publication-title: Drug Metab Dispos – volume: 83 start-page: 279 year: 2012 end-page: 285 ident: bib44 article-title: Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum publication-title: Biochem Pharmacol – volume: 29 start-page: 2860 year: 2012 end-page: 2873 ident: bib45 article-title: Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions publication-title: Pharm Res – volume: 9 start-page: 237 year: 2013 end-page: 252 ident: bib8 article-title: Species differences in drug transporters and implications for translating preclinical findings to humans publication-title: Expert Opin Drug Metab Toxicol – volume: 55 start-page: 4740 year: 2012 end-page: 4763 ident: bib20 article-title: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions publication-title: J Med Chem – volume: 40 start-page: 83 year: 2012 end-page: 92 ident: bib30 article-title: Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities publication-title: Drug Metab Dispos – volume: 283 start-page: 1552 year: 1997 end-page: 1562 ident: bib31 article-title: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism publication-title: J Pharmacol Exp Ther – volume: 9 start-page: 3535 year: 2012 end-page: 3542 ident: bib21 article-title: Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes publication-title: Mol Pharm – volume: 3 start-page: 276 year: 2010 end-page: 285 ident: bib4 article-title: Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study publication-title: Circ Cardiovasc Genet – volume: 281 start-page: 26501 year: 2006 end-page: 26511 ident: bib35 article-title: Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1) publication-title: J Biol Chem – volume: 75 start-page: 455 year: 2004 end-page: 463 ident: bib38 article-title: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin publication-title: Clin Pharmacol Ther – volume: 75 start-page: 415 year: 2004 end-page: 421 ident: bib27 article-title: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics publication-title: Clin Pharmacol Ther – volume: 52 start-page: 235 year: 2002 end-page: 236 ident: bib24 article-title: Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen publication-title: Br J Gen Pract – volume: 27 start-page: 425 year: 2006 end-page: 446 ident: bib40 article-title: Transporters as a determinant of drug clearance and tissue distribution publication-title: Eur J Pharm Sci – volume: 30 start-page: 1188 year: 2013 end-page: 1199 ident: bib46 article-title: Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide publication-title: Pharm Res – volume: 40 start-page: 1085 year: 2012 end-page: 1092 ident: bib6 article-title: In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation publication-title: Drug Metab Dispos – volume: 12 start-page: 5815 year: 2011 end-page: 5827 ident: bib34 article-title: Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response publication-title: Int J Mol Sci – volume: 17 start-page: 861 year: 2012 end-page: 868 ident: bib37 article-title: Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults publication-title: Antivir Ther – volume: 34 start-page: 2 year: 2013 end-page: 28 ident: bib13 article-title: Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption publication-title: Biopharm Drug Dispos – volume: 66 start-page: 818 year: 2008 end-page: 825 ident: bib17 article-title: The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range publication-title: Br J Clin Pharmacol – volume: 15 start-page: 513 year: 2005 end-page: 522 ident: bib18 article-title: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells publication-title: Pharmacogenet Genomics – volume: 87 start-page: 558 year: 2010 end-page: 562 ident: bib43 article-title: ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin publication-title: Clin Pharmacol Ther – volume: 54 start-page: 1609 year: 2009 end-page: 1616 ident: bib47 article-title: The SLCO1B1*5 genetic variant is associated with statin-induced side effects publication-title: J Am Coll Cardiol – volume: 109 start-page: 261 year: 2000 end-page: 262 ident: bib2 article-title: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil publication-title: Am J Med – volume: 20 start-page: 112 year: 2010 end-page: 120 ident: bib12 article-title: HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms publication-title: Pharmacogenet Genomics – volume: 40 start-page: 295 year: 2012 end-page: 312 ident: bib23 article-title: Pharmacokinetic/pharmacodynamic modeling in inflammation publication-title: Crit Rev Biomed Eng – volume: 717 start-page: 67 year: 2012 end-page: 76 ident: bib14 article-title: Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues publication-title: Anal Chim Acta – volume: 276 start-page: 35669 year: 2001 end-page: 35675 ident: bib42 article-title: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans publication-title: J Biol Chem – volume: 25 start-page: 1469 year: 2008 end-page: 1483 ident: bib19 article-title: Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria publication-title: Pharm Res – volume: 14 start-page: 429 year: 2004 end-page: 440 ident: bib28 article-title: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) publication-title: Pharmacogenetics – volume: 311 start-page: 228 year: 2004 end-page: 236 ident: bib39 article-title: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil publication-title: J Pharmacol Exp Ther – volume: 89 start-page: 210 year: 2011 end-page: 216 ident: bib10 article-title: Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study publication-title: Clin Pharmacol Ther – volume: 40 start-page: 852 year: 2012 end-page: 855 ident: bib9 article-title: Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry publication-title: Drug Metab Dispos – volume: 5 start-page: 1 year: 2013 end-page: 11 ident: bib29 article-title: Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 publication-title: Genome Med – volume: 50 start-page: 441 year: 2012 end-page: 448 ident: bib41 article-title: SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians publication-title: Clin Chem Lab Med – volume: 84 start-page: 1 year: 2012 end-page: 8 ident: bib5 article-title: Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family publication-title: J Proteomics Bioinform – volume: 102 start-page: 787 year: 2013 end-page: 793 ident: bib33 article-title: Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype publication-title: J Pharm Sci – volume: 359 start-page: 789 year: 2008 end-page: 799 ident: bib22 article-title: SLCO1B1 variants and statin-induced myopathy—a genomewide study publication-title: N Engl J Med – volume: 9 start-page: 215 year: 2010 end-page: 236 ident: bib11 article-title: Membrane transporters in drug development publication-title: Nat Rev Drug Discov – volume: 44 start-page: 62 year: 2006 end-page: 74 ident: bib26 article-title: Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver publication-title: Hepatology – volume: 25 start-page: 1715 year: 2011 ident: 10.1124/dmd.113.053819_bib48 article-title: Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples publication-title: Rapid Commun Mass Spectrom doi: 10.1002/rcm.5026 – volume: 84 start-page: 1 year: 2012 ident: 10.1124/dmd.113.053819_bib5 article-title: Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family publication-title: J Proteomics Bioinform – volume: 89 start-page: 210 year: 2011 ident: 10.1124/dmd.113.053819_bib10 article-title: Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2010.255 – volume: 66 start-page: 818 year: 2008 ident: 10.1124/dmd.113.053819_bib17 article-title: The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2008.03287.x – volume: 18 start-page: 937 year: 2008 ident: 10.1124/dmd.113.053819_bib16 article-title: Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e32830d733e – volume: 50 start-page: 441 year: 2012 ident: 10.1124/dmd.113.053819_bib41 article-title: SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians publication-title: Clin Chem Lab Med doi: 10.1515/cclm.2011.804 – volume: 17 start-page: 861 year: 2012 ident: 10.1124/dmd.113.053819_bib37 article-title: Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults publication-title: Antivir Ther doi: 10.3851/IMP2095 – volume: 55 start-page: 4740 year: 2012 ident: 10.1124/dmd.113.053819_bib20 article-title: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions publication-title: J Med Chem doi: 10.1021/jm300212s – volume: 44 start-page: 62 year: 2006 ident: 10.1124/dmd.113.053819_bib26 article-title: Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver publication-title: Hepatology doi: 10.1002/hep.21214 – volume: 40 start-page: 1085 year: 2012 ident: 10.1124/dmd.113.053819_bib6 article-title: In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation publication-title: Drug Metab Dispos doi: 10.1124/dmd.111.043489 – volume: 276 start-page: 35669 year: 2001 ident: 10.1124/dmd.113.053819_bib42 article-title: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans publication-title: J Biol Chem doi: 10.1074/jbc.M103792200 – volume: 83 start-page: 279 year: 2012 ident: 10.1124/dmd.113.053819_bib44 article-title: Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2011.10.017 – volume: 717 start-page: 67 year: 2012 ident: 10.1124/dmd.113.053819_bib14 article-title: Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues publication-title: Anal Chim Acta doi: 10.1016/j.aca.2011.12.005 – volume: 40 start-page: 295 year: 2012 ident: 10.1124/dmd.113.053819_bib23 article-title: Pharmacokinetic/pharmacodynamic modeling in inflammation publication-title: Crit Rev Biomed Eng doi: 10.1615/CritRevBiomedEng.v40.i4.50 – volume: 3 start-page: 276 year: 2010 ident: 10.1124/dmd.113.053819_bib4 article-title: Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study publication-title: Circ Cardiovasc Genet doi: 10.1161/CIRCGENETICS.109.898502 – volume: 15 start-page: 513 year: 2005 ident: 10.1124/dmd.113.053819_bib18 article-title: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells publication-title: Pharmacogenet Genomics doi: 10.1097/01.fpc.0000170913.73780.5f – volume: 52 start-page: 235 year: 2002 ident: 10.1124/dmd.113.053819_bib24 article-title: Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen publication-title: Br J Gen Pract – volume: 14 start-page: 429 year: 2004 ident: 10.1124/dmd.113.053819_bib28 article-title: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) publication-title: Pharmacogenetics doi: 10.1097/01.fpc.0000114750.08559.32 – volume: 87 start-page: 558 year: 2010 ident: 10.1124/dmd.113.053819_bib43 article-title: ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2009.232 – volume: 30 start-page: 1188 year: 2013 ident: 10.1124/dmd.113.053819_bib46 article-title: Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide publication-title: Pharm Res doi: 10.1007/s11095-012-0956-5 – volume: 281 start-page: 26501 year: 2006 ident: 10.1124/dmd.113.053819_bib35 article-title: Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1) publication-title: J Biol Chem doi: 10.1074/jbc.M601917200 – volume: 75 start-page: 455 year: 2004 ident: 10.1124/dmd.113.053819_bib38 article-title: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2003.12.014 – volume: 311 start-page: 228 year: 2004 ident: 10.1124/dmd.113.053819_bib39 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.104.068536 – volume: 72 start-page: 685 year: 2002 ident: 10.1124/dmd.113.053819_bib3 article-title: Gemfibrozil greatly increases plasma concentrations of cerivastatin publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2002.128469 – volume: 102 start-page: 787 year: 2013 ident: 10.1124/dmd.113.053819_bib33 article-title: Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype publication-title: J Pharm Sci doi: 10.1002/jps.23436 – volume: 12 start-page: 5815 year: 2011 ident: 10.1124/dmd.113.053819_bib34 article-title: Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response publication-title: Int J Mol Sci doi: 10.3390/ijms12095815 – volume: 201 start-page: 731 year: 2001 ident: 10.1124/dmd.113.053819_bib7 article-title: [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil] publication-title: Rev Clin Esp doi: 10.1016/S0014-2565(01)70966-6 – volume: 40 start-page: 852 year: 2012 ident: 10.1124/dmd.113.053819_bib9 article-title: Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry publication-title: Drug Metab Dispos doi: 10.1124/dmd.111.043810 – volume: 9 start-page: 237 year: 2013 ident: 10.1124/dmd.113.053819_bib8 article-title: Species differences in drug transporters and implications for translating preclinical findings to humans publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.2013.741589 – volume: 109 start-page: 261 year: 2000 ident: 10.1124/dmd.113.053819_bib2 article-title: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil publication-title: Am J Med doi: 10.1016/S0002-9343(00)00514-3 – volume: 20 start-page: 112 year: 2010 ident: 10.1124/dmd.113.053819_bib12 article-title: HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e328335b02d – volume: 75 start-page: 415 year: 2004 ident: 10.1124/dmd.113.053819_bib27 article-title: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2003.12.016 – volume: 25 start-page: 1469 year: 2008 ident: 10.1124/dmd.113.053819_bib19 article-title: Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria publication-title: Pharm Res doi: 10.1007/s11095-008-9532-4 – volume: 359 start-page: 789 year: 2008 ident: 10.1124/dmd.113.053819_bib22 article-title: SLCO1B1 variants and statin-induced myopathy—a genomewide study publication-title: N Engl J Med doi: 10.1056/NEJMoa0801936 – volume: 5 start-page: 1 year: 2013 ident: 10.1124/dmd.113.053819_bib29 article-title: Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 publication-title: Genome Med doi: 10.1186/gm405 – volume: 34 start-page: 2 year: 2013 ident: 10.1124/dmd.113.053819_bib13 article-title: Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption publication-title: Biopharm Drug Dispos doi: 10.1002/bdd.1810 – volume: 27 start-page: 425 year: 2006 ident: 10.1124/dmd.113.053819_bib40 article-title: Transporters as a determinant of drug clearance and tissue distribution publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2005.12.003 – volume: 54 start-page: 1609 year: 2009 ident: 10.1124/dmd.113.053819_bib47 article-title: The SLCO1B1*5 genetic variant is associated with statin-induced side effects publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2009.04.053 – volume: 29 start-page: 2860 year: 2012 ident: 10.1124/dmd.113.053819_bib45 article-title: Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions publication-title: Pharm Res doi: 10.1007/s11095-012-0792-7 – volume: 40 start-page: 93 year: 2012 ident: 10.1124/dmd.113.053819_bib36 article-title: Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes publication-title: Drug Metab Dispos doi: 10.1124/dmd.111.042275 – volume: 9 start-page: 3535 year: 2012 ident: 10.1124/dmd.113.053819_bib21 article-title: Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes publication-title: Mol Pharm doi: 10.1021/mp300379q – volume: 9 start-page: 215 year: 2010 ident: 10.1124/dmd.113.053819_bib11 article-title: Membrane transporters in drug development publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3028 – volume: 40 start-page: 83 year: 2012 ident: 10.1124/dmd.113.053819_bib30 article-title: Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities publication-title: Drug Metab Dispos doi: 10.1124/dmd.111.042259 – volume: 283 start-page: 1552 year: 1997 ident: 10.1124/dmd.113.053819_bib31 article-title: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)37149-6 |
SSID | ssj0014439 |
Score | 2.494532 |
Snippet | Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked... |
SourceID | pubmedcentral proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 78 |
SubjectTerms | Adolescent Adult Aged Aged, 80 and over Alleles ATP Binding Cassette Transporter, Subfamily B ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics Carbamates - metabolism Child Child, Preschool Chromatography, Liquid - methods Female Fluorobenzenes - metabolism Haplotypes - genetics Hepatocytes - metabolism Humans Individuality Infant Liver - metabolism Male Middle Aged Organic Anion Transporters - genetics Piperidines - metabolism Polymorphism, Single Nucleotide - genetics Pyrimidines - metabolism Rosuvastatin Calcium Sulfonamides - metabolism Tandem Mass Spectrometry - methods Young Adult |
Title | Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex |
URI | https://dx.doi.org/10.1124/dmd.113.053819 https://www.ncbi.nlm.nih.gov/pubmed/24122874 https://www.proquest.com/docview/1469214584 https://pubmed.ncbi.nlm.nih.gov/PMC3876790 |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF615YUXxE24tEiogBKH2Lt2vLylITQCilKUor5ZPtatpdROkxgafjC_g9nDV9pK0BfL8pF1PPPtHJ6dD6HXYUyckPLY4CF3DUoD0wCrGBq-Q0O4hZsOl1W-35zxEf18bB9vbZ_XqpbyVdANf1-5ruQmUoVjIFexSvY_JFv-KByAfZAvbEHCsP0nGct0XlItqfoBga_quy1X8435XPZjVestw_YghScxynbmIkkwyWYQiMK0EXHVrHli7M_WYSbbNyRCMdzB3nDPFMmDiT42utDFs7Io5DD3Vb2R0iTwZr8m53kSibYFGbjDuiV2eyqy1WftA3DWJen9SrTRzOZrXZCsqVKE77rP00xkhuW0pZjfZX0pv6h70h8X-YngvwYlnhVEH1FSFqGVU_7CX2otPvVPfvlllc_op2aH--6vQWBRWYiUz5VDPUiXp1XV5DiTRH7DbJFyGK896raH3fagW8-amHQjazKtlu2kjfrYSdUwXL2AUZ1oYVqtiaunUnusZzDb1i29tSGxYMCepAkuLQ21LiFKmQ3FYlQ4IO7Vps2ioI_RWSRoeLowd7rK1tT0fH4mFR2cMkvQGFQmviy8nBwMCdi_Putto1sWRFaC9OPLYfXhjVKiIkb9l3SfUxj8fXNo0UVbj3OdS3c5ZNusPK65ctO76I6OwfBAAeoe2uLpfbSrZbLu4Pr77-BdXJfWA_RnA3W4hjqcpFijDmvU4cuow3XUYRA_bqIOv5WYe4c14nCFuA-4iTccrLHCG27iDSu8YYE3XMebHK_EG85iXOCtgwFtHXkesPYQHX0aTYdjQ7OlGCFEMSuYbGnAIocElst46LMIXrJDHCYKIWxmu2ZMuMtc34cgx3ZjRoJ-7LgO4w74sXZIyCO0k2Ypf4KwTwlM2pSQmHJKY-6GMTV7JOD9KHAYi1vIKATuhZpKQDDazDyZUrCoB7oCO8RTutJCb8rr56qJzrVXmoX-eDoEUK69BzC49p5XhaJ5YBvFB08_5Vm-FGkNJpgYXNpCj5XileMXyttC_YZKlheIvvvNM2lyKvvvawQ9vfGdz9Dtak56jnZWi5y_gNhmFbyUaPwLhsxd9A |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interindividual+Variability+in+Hepatic+Organic+Anion-Transporting+Polypeptides+and+P-Glycoprotein+%28ABCB1%29+Protein+Expression%3A+Quantification+by+Liquid+Chromatography+Tandem+Mass+Spectroscopy+and+Influence+of+Genotype%2C+Age%2C+and+Sex&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Prasad%2C+Bhagwat&rft.au=Evers%2C+Raymond&rft.au=Gupta%2C+Anshul&rft.au=Hop%2C+Cornelis+E.+C.+A.&rft.date=2014-01-01&rft.pub=The+American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.eissn=1521-009X&rft.volume=42&rft.issue=1&rft.spage=78&rft.epage=88&rft_id=info:doi/10.1124%2Fdmd.113.053819&rft_id=info%3Apmid%2F24122874&rft.externalDocID=PMC3876790 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon |